Critical evaluation of latanoprostene bunod in the treatment of glaucoma

Giancarlo A Garcia, Philip Ngai, Sameh Mosaed, Ken Y Lin Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA Abstract: Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2α receptor agonist in clinic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Garcia GA, Ngai P, Mosaed S, Lin KY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	uveoscleral outflow glaucoma medical treatment ocular hypertension latanoprostene bunod nitric oxide clinical trial Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d67d8233ff134794a81313669bfa3f40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d67d8233ff134794a81313669bfa3f40
record_format	dspace
spelling	oai:doaj.org-article:d67d8233ff134794a81313669bfa3f402021-12-02T00:37:24ZCritical evaluation of latanoprostene bunod in the treatment of glaucoma1177-5483https://doaj.org/article/d67d8233ff134794a81313669bfa3f402016-10-01T00:00:00Zhttps://www.dovepress.com/critical-evaluation-of-latanoprostene-bunod-in-the-treatment-of-glauco-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Giancarlo A Garcia, Philip Ngai, Sameh Mosaed, Ken Y Lin Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA Abstract: Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2α receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated. Keywords: uveoscleral outflow, glaucoma medical treatment, ocular hypertension, latanoprostene bunod, nitric oxide, clinical trialGarcia GANgai PMosaed SLin KYDove Medical Pressarticleuveoscleral outflowglaucoma medical treatmentocular hypertensionlatanoprostene bunodnitric oxideclinical trialOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 2035-2050 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	uveoscleral outflow glaucoma medical treatment ocular hypertension latanoprostene bunod nitric oxide clinical trial Ophthalmology RE1-994
spellingShingle	uveoscleral outflow glaucoma medical treatment ocular hypertension latanoprostene bunod nitric oxide clinical trial Ophthalmology RE1-994 Garcia GA Ngai P Mosaed S Lin KY Critical evaluation of latanoprostene bunod in the treatment of glaucoma
description	Giancarlo A Garcia, Philip Ngai, Sameh Mosaed, Ken Y Lin Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA Abstract: Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2α receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated. Keywords: uveoscleral outflow, glaucoma medical treatment, ocular hypertension, latanoprostene bunod, nitric oxide, clinical trial
format	article
author	Garcia GA Ngai P Mosaed S Lin KY
author_facet	Garcia GA Ngai P Mosaed S Lin KY
author_sort	Garcia GA
title	Critical evaluation of latanoprostene bunod in the treatment of glaucoma
title_short	Critical evaluation of latanoprostene bunod in the treatment of glaucoma
title_full	Critical evaluation of latanoprostene bunod in the treatment of glaucoma
title_fullStr	Critical evaluation of latanoprostene bunod in the treatment of glaucoma
title_full_unstemmed	Critical evaluation of latanoprostene bunod in the treatment of glaucoma
title_sort	critical evaluation of latanoprostene bunod in the treatment of glaucoma
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/d67d8233ff134794a81313669bfa3f40
work_keys_str_mv	AT garciaga criticalevaluationoflatanoprostenebunodinthetreatmentofglaucoma AT ngaip criticalevaluationoflatanoprostenebunodinthetreatmentofglaucoma AT mosaeds criticalevaluationoflatanoprostenebunodinthetreatmentofglaucoma AT linky criticalevaluationoflatanoprostenebunodinthetreatmentofglaucoma
_version_	1718403648250183680

Critical evaluation of latanoprostene bunod in the treatment of glaucoma

Ejemplares similares